Skip to content

Molecule Screening Engine reference profile.

Which candidate molecules from a screening library are worth advancing to the next stage of experimental validation?

PharmaBiotechLife SciencesDrug DiscoveryRanking
Share
AI summary

Overview

Narrows huge virtual libraries down to a shortlist worth spending wet-lab budget on.

Who owns this decision

VP Drug Discovery, Head of Computational Chemistry

What this Specialist Model actually does

Decision: Which candidate molecules from a screening library are worth advancing to the next stage of experimental validation?

The final taxonomy records 6 supporting or external components, but it doesn't promote an Oumi-owned specialist model for this engine.

Who uses this Specialist Model

  • VP Drug Discovery
  • Head of Computational Chemistry
  • Chief Scientific Officer
  • Director of Preclinical Research

Where the specialist model sits

The final taxonomy records 6 supporting or external components, but it doesn't promote an Oumi-owned specialist model for this engine.

Retrieval over internal assay history and literature

Supporting component

See search reasoning models →

Ranking layer combining predicted properties into a priority score

Supporting component

See forecast models →

Chemist review and override interface

Supporting component

How Oumi connects to your stack →

Molecular representation/featurization pipeline (fingerprints, graph embeddings)

Supporting component

How Oumi connects to your stack →

Dedicated property-prediction models (ADMET, docking) outside the general LLM stack

Supporting component

See forecast models →

General reasoning model

Supporting component

General reasoning model for literature synthesis and rationale generation

See generation models →

How to evaluate and improve it

Evaluation

  • Enrichment factor (true actives found in top-ranked subset)
  • Correlation between predicted and assayed properties
  • False-negative rate on known actives (held-out)

Feedback signals

  • Wet-lab assay result confirms or contradicts prediction
  • Molecule advances to next stage or is dropped
  • Synthesis difficulty encountered that wasn't predicted
  • Toxicity or off-target effect discovered downstream
  • Chemist override of a priority ranking
  • Patent landscape change affecting viability

Reference profile

Oumi doesn't recommend an Oumi-owned specialist model for this engine's core decision.

Atlas of AI. Recommendations require validation against your data and operating constraints.